Cancer

November 12, 2018

Probiotic-based therapy for Acute Myeloid Leukemia: Lactobacillus rhamnosus decreases the expression of BCLAF1,  promotes differentiation of acute myeloid leukemic cells, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and promotes regression of AML via up-regulation of its target gene, 12/August/2018, 10.40 pm

Introduction: What they say: A study from the Institute of Genetics and Biophysics, CNR, Naples, Italy; and Department of Biochemistry, Biophysics and General Pathology, Second University […]
November 12, 2018

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as FOXO1, CADM2,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 12/November/2018, 8.01 pm

Introduction: What they say: A study from the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology […]
November 12, 2018

Probiotic-based anticancer therapy: Probiotic Lactobacillus Rhamnosus increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells, via up-regulation of its target gene, 12/November/2017, 7.41 pm

Introduction: What they say: A study from the Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts, USA, Department of Biology, Massachusetts Institute of Technology, […]
November 6, 2018

Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as IGFBP3, PIAS3, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 6/November/2018,11.28 pm

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows […]